Literature DB >> 196941

Cholinergic, adrenergic, and purinergic neuromuscular transmission.

G Burnstock.   

Abstract

A general model of the autonomic neuromuscular junction is proposed which emphasizes muscle effector bundles with gap junctions (or 'nexuses') forming the low resistance pathways allowing electrotonic coupling between neighboring cells, and extensive terminal varicose nerve fibers with 'en passage' release of transmitter. Some variations in autonomic neuromuscular geometry are discussed. Junctional clefts vary from 15nm in densely-innervated tissues such as vas deferens and iris to 2,000 nm in some large elastic arteries. Postjunctional specializations take the form of subsynaptic cysternae (in vas deferens and iris) and aggregations of plasmalemmal vesicles (in circular intestinal muscle). Current views of the synthesis, storage, release, and inactivation of transmitter during cholinergic, adrenergic, and purinergic transmission are summarized.

Mesh:

Substances:

Year:  1977        PMID: 196941

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  5 in total

Review 1.  Synaptic and nonsynaptic transmission: a historical perspective.

Authors:  E Florey
Journal:  Neurochem Res       Date:  1984-03       Impact factor: 3.996

2.  Quinacrine accumulates in certain peptide hormone-producing cells.

Authors:  M Ekelund; B Ahrén; R Håkanson; I Lundquist; F Sundler
Journal:  Histochemistry       Date:  1980

3.  Bombesin-, gastrin/CCK-, 5-hydroxytryptamine-, neurotensin-, somatostatin-, and VIP-like immunoreactivity and catecholamine fluorescence in the gut of the elasmobranch, Squalus acanthias.

Authors:  S Holmgren; S Nilsson
Journal:  Cell Tissue Res       Date:  1983       Impact factor: 5.249

4.  VIP-, substance P-, gastrin/CCK-, bombesin-, somatostatin- and glucagon-like immunoreactivities in the gut of the rainbow trout, Salmo gairdneri.

Authors:  S Holmgren; C Vaillant; R Dimaline
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

Review 5.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.